Brokerages Set Edwards Lifesciences Corporation (NYSE:EW) PT at $91.39

Shares of Edwards Lifesciences Corporation (NYSE:EW) have earned an average recommendation of “Moderate Buy” from the twenty-eight brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation, fourteen have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $91.3913.

Several equities research analysts have recently issued reports on the stock. Evercore ISI increased their price objective on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Tuesday, July 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Finally, UBS Group reissued a “neutral” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, November 3rd.

Edwards Lifesciences Price Performance

EW opened at $85.14 on Wednesday. The stock has a market cap of $49.41 billion, a P/E ratio of 12.25, a P/E/G ratio of 3.97 and a beta of 1.03. Edwards Lifesciences has a 12 month low of $64.89 and a 12 month high of $87.09. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $77.90 and a 200 day simple moving average of $77.53.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the firm earned $0.67 earnings per share. The company’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts expect that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 22,970 shares of company stock worth $1,862,878 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in Edwards Lifesciences in the first quarter valued at approximately $26,000. SouthState Corp acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $27,000. Rosenberg Matthew Hamilton bought a new position in Edwards Lifesciences in the 2nd quarter valued at about $28,000. True Wealth Design LLC boosted its holdings in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares during the period. Finally, Costello Asset Management INC acquired a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $29,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.